A pioneering team at St Jude Children's Research Hospital in the US say they successfully treated a child diagnosed with SMA ...
Le gel de l'aide étrangère par le gouvernement américain a bouleversé la chaîne d'approvisionnement en produits médicaux ...
Roche dévoile une technologie exclusive et révolutionnaire de séquençage par expansion , qui 'offre un séquençage ...
Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is the third treatment approved for SMA ...
a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi® (risdiplam ...
A mother was given SMA treatment Evrysdi during pregnancy, and her child with SMA, now 2.5, has not shown any signs of the ...
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial ...
Medpage Today on MSN3d
First-Ever Prenatal Treatment for Spinal Muscular Atrophy Shows PromiseThe first prenatal therapy for spinal muscular atrophy (SMA) showed promising results, a case report indicated. More than 2 ...
Basel: Roche, announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi (risdiplam) tablet for people living with spinal muscular atrophy (SMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback